{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:00:31Z","timestamp":1780614031561,"version":"3.54.1"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,1,15]]},"DOI":"10.2169\/internalmedicine.9157-21","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T22:10:18Z","timestamp":1655763018000},"page":"281-284","source":"Crossref","is-referenced-by-count":4,"title":["Successful Treatment with Low-dose Crizotinib in a Patient with &lt;i&gt;ROS1&lt;\/i&gt;-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure"],"prefix":"10.2169","volume":"62","author":[{"given":"Takahiko","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Anjo Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Anjo Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Okumura","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Anjo Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuki","family":"Fukatsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Anjo Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Anjo Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer, <i>ROS1<\/i> and <i>RET<\/i> fusions. Oncologist 18: 865-875, 2013.","DOI":"10.1634\/theoncologist.2013-0095"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in <i>ROS1<\/i>-rearranged non-small-cell lung cancer. N Engl J Med 371: 1963-1971, 2014.","DOI":"10.1056\/NEJMoa1406766"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wu YL, Yang JC, Kim DW, et al. Phase II study of crizotinib in East Asian patients with <i>ROS1<\/i>-positive advanced non-small-cell lung cancer. J Clin Oncol 36: 1405-1411, 2018.","DOI":"10.1200\/JCO.2017.75.5587"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tartarone A, Gallucci G, Lazzari C, Lerose R, Lombardi L, Aieta M. Crizotinib-induced cardiotoxicity, the importance of a proactive monitoring and management. Future Oncol 1: 2043-2048, 2015.","DOI":"10.2217\/fon.15.47"},{"key":"5","unstructured":"5. Full prescribing information. Xalkori [Internet]. [cited 2022 Apr 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202570s030lbl.pdf."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29: 277-314, 2016.","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fukuizumi A, Miyanaga A, Seike M, et al. Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report. BMC Res Notes 8: 165, 2015.","DOI":"10.1186\/s13104-015-1126-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wilner KD, Usari T, Polli A, Kim EE. Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer. Future Oncol 15: 1097-1103, 2019.","DOI":"10.2217\/fon-2018-0869"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol 16: 2029-2039, 2021.","DOI":"10.1016\/j.jtho.2021.07.030"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shim JV, Chun B, van Hasselt JGC, Birtwistle MR, Saucerman JJ, Sobie EA. Mechanistic systems modeling to improve understanding and prediction of cardiotoxicity caused by targeted cancer therapeutic. Front Physiol 8: 651, 2017.","DOI":"10.3389\/fphys.2017.00651"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Harbeck N, Ewer MS, De Laurentiis M, Suter TM, Ewer SM. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann Oncol 22: 1250-1258, 2011.","DOI":"10.1093\/annonc\/mdq543"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Kunimasa K, Oka T, Hara S, et al. Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer 153: 186-192, 2021.","DOI":"10.1016\/j.lungcan.2020.10.021"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Satoh H, Inoue A, Kobayashi K, et al. Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 6: 1413-1417, 2011.","DOI":"10.1097\/JTO.0b013e31821d43a8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yang JC, Sequist LV, Zhou C, et al. Effect of dose adjustment on the safety and efficacy of afatinib for <i>EGFR<\/i> mutation-positive lung adenocarcinoma: <i>post hoc<\/i> analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol 27: 2103-2110, 2016.","DOI":"10.1093\/annonc\/mdw322"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/2\/62_9157-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T03:25:41Z","timestamp":1674271541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/2\/62_9157-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,15]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9157-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,15]]},"article-number":"9157-21"}}